Probiotics and synbiotics targeting the intestinal microbiome attenuate non-alcoholic fatty liver disease

作     者：Luis Vitetta Jeremy D.Henson Luis Vitetta;Jeremy D. Henson

作者机构：Faculty of Medicine and HealthSydney School of MedicineThe University of SydneySydneyAustralia Medlab Clinical SydneySydneyAustralia Faculty of MedicinePrince of Wales Clinical SchoolUniversity of New South WalesSydneyAustralia 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2020年第9卷第4期

页      面：526-529页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：NAFLD liver cardiovascular 

摘      要：Non-alcoholic fatty liver disease(NAFLD)presents a chronic condition that links the overarching influence of the intestinal microbiome to a disease state with the multisystem manifestations of obesity,type 2 diabetes(T2D),chronic kidney disease(CKD)and cardiovascular disease(CVD)(1).NAFLD is an increasingly common disease with a current prevalence of 25%worldwide(2).The proportion of severe presentations of NAFLD is also increasing and these trends will lead to an increased burden from NAFLD sequelae,including cirrhosis,liver failure and hepatocellular cancer(2).